Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company's strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC's technology will be used to analyze Lisata's lead candidate certepetide and identify potential new drug combinations.
BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the Investival Showcase USA, taking place March 10-11, 2025 in Miami, Florida.
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The partnership combines GATC's proprietary Multiomics Advanced Technology (MAT) AI platform with Lisata's expertise in drug development to reduce risks and improve efficiency in bringing new therapies to market.
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process.
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical company highlighted progress in its clinical pipeline, including encouraging preliminary data from a Phase 2b pancreatic cancer trial.
Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCEND trial at the ASCO Gastrointestinal conference.
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The iLSTA trial is being conducted at St John of God Subiaco Hospital in Western Australia, involving 30 patients divided into three treatment cohorts.
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is evaluating the efficacy of Lisata's novel therapy certepetide in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive form of pancreatic cancer.
BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming Sequire Investor Summit being held January 21-23, 2025 in San Juan, Puerto Rico.
Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company announced the completion of patient enrollment in the Phase 1b/2a CENDIFOX trial, evaluating its iRGD cyclic peptide, certepetide, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.